Combining cBTKi treatment with CAR T-cell therapy may be a strategy that can overcome the resistance of CLL to CD19-targeted CAR T-cell therapies and improve responses [51]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.